At a glance
ClinicalIndex Comparison RecordPhase 3Completed· 758 enrolled
Drug / intervention
enzastaurin +1 moredrug
Likely dose
enzastaurin 1125 mgfrom record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
A Phase 3 Clinical Study to Investigate the Prevention of Relapse in Lymphoma Using Daily Enzastaurin
In Brief
A Phase 3 clinical trial evaluating enzastaurin and placebo for Non Hodgkin Lymphoma. Completed, enrolled 758 participants across 153 sites in 25 countries.
Detailed Summary
This clinical research study is to investigate the prevention of relapse in patients with diffuse large B cell lymphoma (DLBCL) using enzastaurin daily. This is a randomised trial which compares Enzastaurin to Placebo (dummy treatment), the chance of receiving Enzastaurin is 2 to 1.
Study Details
Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsNon Hodgkin Lymphoma
CountriesAustralia, Belgium, Brazil, Canada, China, Czechia, Denmark, Finland, France, Germany, Greece, Hungary, India, Italy, Japan, Mexico, Poland, Portugal, Puerto Rico, South Korea, Spain, Sweden, Taiwan, United Kingdom, United States
Collaborators--
Timeline
Phase 3CompletedFinished
2006200720082009201020112012201320142015201620172018201920202021202220232024202520262027
First PostedJun 2006
Enrollment StartJun 2006
Primary CompletionApr 2013
Study CompletionJul 2013
TodayJul 2026
First PostedJun 1, 2006
Enrollment StartJun 1, 2006
Primary CompletionApr 1, 2013
Study CompletionJul 1, 2013
TodayJul 2, 2026
Enrollment to primary: 6.8 yearsPosted 20.1 years ago
Interventions
enzastaurindrug
1125 mg loading dose then 500 mg, oral, daily, until disease progression or maximum of 3 years
placebodrug
oral, daily